D-0940-2020 Class II Terminated
FDA drug recall D-0940-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
AscorbiX (Buffered C) Injection, Ascorbix (50ML) 500MG/ML Injectable, For IV, IM, SC Use, Refrigerate, 30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0226-5
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Code information
Lot #: 08222019+52828, Exp 2/28/2020; 09092019+52889, Exp 3/17/2020; 09182019+52924, Exp 3/26/2020; 09262019+52971, Exp 4/3/2020; 10142019+53108, Exp 4/21/2020; 10212019+53136, Exp 4/28/2020; 10302019+53164, Exp 5/7/2020; 11252019+53278, Exp 6/2/2020; 11262019+53284, Exp 6/3/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0940-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026